Key Highlights

  • Abbott Laboratories (NYSE:ABT) reported third-quarter sales of USD 13.01 billion on Wednesday, October 21, 2026, up 7.0% on a comparable basis, and tightened 2026 EPS guidance to USD 5.50 to USD 5.55, yet its shares fell.
  • Dexcom (NASDAQ:DXCM) fell about 6% to 6.5% on the same day, while the S&P 500 rose 0.58%, after Abbott reported continuous glucose monitor sales growth of 7.7%.
  • Danaher (NYSE:DHR) earned USD 2.11 per share in adjusted terms, raised 2026 EPS guidance to USD 8.57 to USD 8.62 and bounced higher after trading lower before the open.
  • Thermo Fisher Scientific (NYSE:TMO) beat revenue estimates by about USD 200 million at USD 12.14 billion, raised 2026 revenue guidance to USD 47.7 billion to USD 48.2 billion and closed about 4% higher.

Abbott Laboratories (NYSE:ABT): a beat with a narrower range

Abbott Laboratories (NYSE:ABT), a diversified healthcare group spanning medical devices, diagnostics, nutrition and branded generic drugs, reported third-quarter results on Wednesday, October 21, 2026. Sales were USD 13.01 billion, up 14.5% reported and 7.0% on a comparable basis, and adjusted EPS rose 9.2% to USD 1.42. Diagnostics reached USD 3.31 billion, up 46.7% reported after the acquisition of Exact Sciences, completed on Monday, March 23, 2026. Abbott tightened 2026 adjusted EPS guidance to USD 5.50 to USD 5.55, reaffirming the midpoint, and announced plans to separate its Nutrition business. The shares fell on the day.

The tension sits between earnings and growth. The comparable sales growth outlook of about 6.0% sits below the 7.0% delivered in the quarter, and press reports read it as a trimmed growth outlook, although the company reaffirmed its EPS midpoint. Diabetes Care, home to the FreeStyle Libre sensors, grew 6.7% to USD 2.19 billion, with monitor sales up 7.7%. For a category valued mainly on growth, a pace below 8% can pressure multiples across the group, which is how the numbers reached Dexcom. The risks are a durable slowdown in monitor growth, stranded costs from the Nutrition separation and integration of Exact Sciences, which now inflates reported growth.

Dexcom (NASDAQ:DXCM): a read-through sell-off before its own report

Dexcom (NASDAQ:DXCM), which makes continuous glucose monitors, wearable sensors that track blood sugar every few minutes, fell about 6% to 6.5% on Wednesday, October 21, 2026. The decline came on a strong day for equities: the S&P 500 rose 0.58%, the Dow Jones Industrial Average gained 0.69% to 52,856 and the Nasdaq Composite added 1.05%. Dexcom had not yet reported its own third-quarter results, so the move was a read-through from Abbott, its main rival through the FreeStyle Libre line, rather than a response to a change in its own guidance.

Abbott's diabetes figures act as the first public read on category demand each quarter, because the two companies hold most of the glucose monitor market. Sensors are disposable and replaced every one to two weeks, which ties recurring revenue to the number of users, so investors value the category on growth. Monitor growth of 7.7% raised the question of whether demand from people with type 2 diabetes is expanding as fast as valuations assume. On simple arithmetic, Dexcom lagged the S&P 500 by about 6.6 to 7.1 percentage points. Read-throughs can overshoot, since Abbott's figures blend pricing, geography and product mix, and faster growth in Dexcom's own report could reverse part of the move.

Danaher (NYSE:DHR): core growth and a higher floor

Danaher (NYSE:DHR), a life sciences and diagnostics group whose businesses include bioprocessing supplier Cytiva and molecular testing company Cepheid, reported third-quarter results before the open on Wednesday, October 21, 2026. Adjusted EPS was USD 2.11, edging past consensus estimates, and revenue rose 8.5% to USD 6.55 billion. Core growth excluding respiratory testing accelerated to 5.5%. Danaher raised its 2026 adjusted EPS guidance to USD 8.57 to USD 8.62. The shares traded lower before the open, then bounced higher during the regular session as the S&P 500 rose 0.58%, and the new chief executive set out a goal of clear market share gains.

Core growth sets the valuation here, because the EPS beat was narrow. The measure removes acquisitions and currency, and excluding respiratory testing also removes demand that swings with flu and COVID seasons, so an acceleration to 5.5% points to steadier underlying orders. Bioprocessing sells filters, resins and media that drugmakers consume as they produce biologic medicines, so revenue recurs with production volumes. The risks are that 5.5% reflects customer restocking rather than sustained demand, a volatile respiratory season and higher expectations under new leadership, with the federal funds range at 3.75% to 4.00% tightening funding for biotechnology customers.

Thermo Fisher Scientific (NYSE:TMO): operating leverage behind a 4% gain

Thermo Fisher Scientific (NYSE:TMO), the largest supplier of laboratory instruments, consumables and outsourced drug development and manufacturing services, reported third-quarter results on Wednesday, October 21, 2026. Revenue rose 9% to USD 12.14 billion, about USD 200 million above consensus estimates, and organic growth was 6%. Adjusted EPS rose 15%, and operating margins expanded. The company raised its 2026 revenue guidance to USD 47.7 billion to USD 48.2 billion, a midpoint of about USD 47.95 billion. The shares dipped early in the session, then reversed to close about 4% higher on a day when the S&P 500 gained 0.58%.

The key relationship is operating leverage, the way profit grows faster than revenue once fixed costs are covered. Revenue up 9% produced adjusted EPS up 15%, a spread of about six percentage points from wider margins. Organic growth of 6% shows demand from existing customers, such as drugmakers buying bioprocessing materials, and a recurring consumables stream makes that demand more predictable than instrument sales. Two large tools suppliers beating on the same morning gave a broader signal on demand. The risks are order timing in bioprocessing, research funding decisions after the midterm elections and rates that weigh on long-duration valuations.

Where Things Stand

The answer is that all four shares were priced on growth rather than on the size of the beats. Abbott Laboratories (NYSE:ABT) beat and held its EPS midpoint, but comparable growth guided to about 6.0% and monitor growth of 7.7% raised doubts about the glucose monitor category, which is why Dexcom (NASDAQ:DXCM) fell about 6% to 6.5% before reporting itself. In life science tools, growth moved the other way: core growth of 5.5% at Danaher (NYSE:DHR) and organic growth of 6% at Thermo Fisher Scientific (NYSE:TMO) came with raised guidance, and both recovered from early weakness. The next catalysts are the Fed decision on Wednesday, October 28, 2026, the midterm elections on Tuesday, November 3, 2026 and Dexcom's own third-quarter report. Guidance is a company forecast, not a guarantee, and this is not investment advice.